Notably, patients with high TLS density exhibit significantly prolonged 2-year recurrence-free survival, reaching up to 81.5% (27); ferroptosis synergy: OV efficacy is augmented by ferroptosis inducers such as Erastin, achieving tumor inhibition rates as high as 72% (28); antigen presentation and epigenetic activation: OV therapy upregulates MHC-I expression and, in combination with EZH2 inhibition, significantly enhances CD8+ T cell tumor recognition, thereby potentiating cytotoxic immune responses (29). The gene discussed is CD8A; the disease is neoplasm.